PB2033: INFLUENCE OF INDUCTION THERAPY WITH LENALIDOMIDE ON MAINTENANCE THERAPY AND PROGNOSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

Bibliographic Details
Main Authors:	Q. Sun, J. Liu, B. Huang, J. Gu, X. Li, J. Li
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850964.23300.15

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
by: Mohamad Mohty, et al.
Published: (2020-05-01)

P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA
by: O. Pasvolsky, et al.
Published: (2022-06-01)

PB2162: EVALUATION OF IMMUNE RECONSTITUTION IN MULTIPLE MYELOMA PATIENTS ON MAINTENANCE THERAPY WITH LENALIDOMIDE - THE ROLE OF HEAVYLITE CHAINS
by: Mariana Miranda, et al.
Published: (2023-08-01)

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy
by: Sini Luoma, et al.
Published: (2023-05-01)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
by: Marc-Andrea Baertsch, et al.
Published: (2021-09-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma
by: James Crosby DO, et al.
Published: (2022-10-01)

P959: MAINTENANCE THERAPY FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANTATION BY IXAZOMIB AND/OR LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTICENTERED REAL WORLD STUDY IN CHINA
by: Minqiu Lu, et al.
Published: (2023-08-01)

Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation✰
by: Minh Phuong Vu, et al.
Published: (2023-01-01)

Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
by: Seunghee Kim-Schulze, et al.
Published: (2024-04-01)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
by: Rishi Agarwal, et al.
Published: (2012-12-01)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
by: Mads Harsløf, et al.
Published: (2023-08-01)

PB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI-CENTER PROSPECTIVE TRIAL
by: H. Wang, et al.
Published: (2022-06-01)

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)
by: Amelie Boquoi, et al.
Published: (2023-10-01)

Refractory postherpetic neuralgia in a multiple myeloma patient with lenalidomide maintenance therapy: a case report
by: Xueqin Cao, et al.
Published: (2022-09-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
by: Z. Zhuang, et al.
Published: (2022-06-01)

PB1978: AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE IMPROVES SURVIVAL, IN COLOMBIAN MULTIPLE MYELOMA PATIENTS. ACHO’S RENEHOC REGISTRY REPORT
by: V. Abello, et al.
Published: (2022-06-01)

P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS
by: G. Barilà, et al.
Published: (2023-05-01)

Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
by: Lalit Kumar, et al.
Published: (2019-08-01)

Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis
by: Ying Chen, et al.
Published: (2024-12-01)

P873: IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: UPDATE OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA
by: Zhe Zhuang, et al.
Published: (2023-08-01)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
by: Yu Han Koh, et al.
Published: (2023-08-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
by: Pieter Sonneveld, et al.
Published: (2022-10-01)

Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma
by: Alpay Yeşilaltay, et al.
Published: (2024-01-01)

Therapy efficacy in multiple myeloma patients received autologous stem cells transplantation as first line therapy
by: Ye. I. Darskaya, et al.
Published: (2014-07-01)

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04
by: C. Touzeau, et al.
Published: (2022-06-01)

Triplet therapy, transplantation, and maintenance until progression in multiple myeloma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Sebastian Grosicki, et al.
Published: (2023-08-01)

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy
by: Charlotte F. M. Hughes, et al.
Published: (2024-03-01)

VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
by: Jakob Nordberg Nørgaard, et al.
Published: (2024-04-01)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
by: Sarah A. Bird, et al.
Published: (2020-05-01)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
by: X. Jingyu, et al.
Published: (2022-06-01)

AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes
by: Michael Ozga, et al.
Published: (2020-11-01)

PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: M. Sasaki, et al.
Published: (2022-06-01)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia
by: Carmine Liberatore, et al.
Published: (2023-11-01)

Maintenance therapy in multiple myeloma
by: Jean-Luc Harousseau
Published: (2009-08-01)

Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study
by: Mads Harsløf, et al.
Published: (2024-04-01)

PB2033: INFLUENCE OF INDUCTION THERAPY WITH LENALIDOMIDE ON MAINTENANCE THERAPY AND PROGNOSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

Similar Items

Similar Items